title: Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of tamsulosin and solifenacin combination therapy compared with tamsulosin monotherapy for male lower urinary tract symptoms (LUTS).
  
  
  METHODS
  We identified all eligible studies that compared tamsulosin and solifenacin combination therapy with tamsulosin monotherapy for male LUTS (up to January 2015). The fixed- or random-effects model was selected depending on the proportion of heterogeneity.
  
  
  RESULTS
  Seven articles were identified as eligible for this meta-analysis, with a total of 3063 participants. Synthetic data showed combination therapy had significant improvements in Storage International Prostate Symptom Score (WMD = -0.60; 95% CI: -0.81 to -0.38, P < 0.0001), quality of life (WMD = -0.23; 95% CI: -0.34 to -0.11, P < 0.0001), micturitions per 24 hours (WMD = -0.70; 95% CI: -0.86 to -0.55, P < 0.0001) and urgency episodes per 24 hours (WMD = -0.26; 95% CI: -0.48 to -0.05, P = 0.018). The incidence of adverse effects in the tamsulosin and solifenacin combined therapy group (30.82%) was similar to the tamsulosin monotherapy group (25.75%). Acute urinary retention was seldom reported in the studies and no clinically significant changes regarding Qmax were showed in our meta-analysis.
  
  
  CONCLUSIONS
  Tamsulosin and solifenacin combination therapy may be a reasonable option for male LUTS patients, especially for those who have significant storage symptoms. However, PVR should be measured during treatment to assess the increase in PVR or the incidence of AUR.
authors.affiliation: a a Department of Urology , Zhongshan Affiliated Hospital of Sun Yat-sen University , Zhongshan , Guangdong , China.
authors.forename: Mancheng
authors.initials: M
authors.lastname: Gong
authors.affiliation: b b Department of Oncology , Zhongshan Affiliated Hospital of Sun Yat-sen University , Zhongshan , Guangdong , China.
authors.forename: Wenjing
authors.initials: W
authors.lastname: Dong
authors.affiliation: c c The Second General Department , Zhongshan Affiliated Hospital of Sun Yat-sen University , Zhongshan , Guangdong , China.
authors.forename: Guiying
authors.initials: G
authors.lastname: Huang
authors.affiliation: a a Department of Urology , Zhongshan Affiliated Hospital of Sun Yat-sen University , Zhongshan , Guangdong , China.
authors.forename: Zhaoyang
authors.initials: Z
authors.lastname: Gong
authors.affiliation: a a Department of Urology , Zhongshan Affiliated Hospital of Sun Yat-sen University , Zhongshan , Guangdong , China.
authors.forename: Decheng
authors.initials: D
authors.lastname: Deng
authors.affiliation: d d Department of Urology , The First Affiliated Hospital of Sun Yat-Sen University , Guangzhou , Guangdong , China.
authors.forename: Shaopeng
authors.initials: S
authors.lastname: Qiu
authors.affiliation: a a Department of Urology , Zhongshan Affiliated Hospital of Sun Yat-sen University , Zhongshan , Guangdong , China.
authors.forename: Runqiang
authors.initials: R
authors.lastname: Yuan
mesh_terms: D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D008297:Male; D017063:Outcome Assessment, Health Care; D011470:Prostatic Hyperplasia / Q000150:complications; D011788:Quality of Life; D000069464:Solifenacin Succinate / Q000008:administration & dosage / Q000009:adverse effects; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects; D000077409:Tamsulosin; D016055:Urinary Retention / Q000139:chemically induced / Q000517:prevention & control; D064804:Urological Agents / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D013449:Sulfonamides; D064804:Urological Agents; D000077409:Tamsulosin; D000069464:Solifenacin Succinate
keywords: BPH; Male LUTS; Meta-analysis; Solifenacin; Tamsulosin